Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines
Metrics: PDF 2150 views | HTML 2777 views | ?
Kamila Kloudová1,3, Hana Hromádková1, Simona Partlová1,3, Tomáš Brtnický2, Lukáš Rob2, Jiřina Bartůňková1, Michal Hensler3, Michael J. Halaška2, Radek Špíšek1,3, Anna Fialová1,3
1Department of Immunology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic
2Department of Obstetrics and Gynaecology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic
3Research Department, Sotio, Prague, Czech Republic
Anna Fialová, email: firstname.lastname@example.org
Keywords: high-grade serous epithelial ovarian cancer, tumor-associated antigens, immunotherapy, cancer cell lines
Received: January 13, 2016 Accepted: May 26, 2016 Published: June 14, 2016
In order to select a suitable combination of cancer cell lines as an appropriate source of antigens for dendritic cell-based immunotherapy of ovarian cancer, we analyzed the expression level of 21 tumor associated antigens (BIRC5, CA125, CEA, DDX43, EPCAM, FOLR1, Her-2/neu, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MUC-1, NY-ESO-1, PRAME, p53, TPBG, TRT, WT1) in 4 established ovarian cancer cell lines and in primary tumor cells isolated from the high-grade serous epithelial ovarian cancer tissue. More than 90% of tumor samples expressed very high levels of CA125, FOLR1, EPCAM and MUC-1 and elevated levels of Her-2/neu, similarly to OVCAR-3 cell line. The combination of OV-90 and OVCAR-3 cell lines showed the highest overlap with patients’ samples in the TAA expression profile.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.